High Dose PPI denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for high dose ppi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies High-Dose PPI as Duplicate Therapy

Cigna's duplicate-therapy denial means its pharmacy or utilization management system has flagged that the patient is already receiving a proton pump inhibitor (PPI) — either the same drug at standard dosing, or a different PPI — and views the additional or escalated prescription as redundant. This can happen when a prescriber escalates from standard to high-dose therapy without a supporting diagnosis code that justifies the higher dose, or when two prescribers have independently prescribed overlapping acid-suppression therapy.

## Why This Denial Is Appealable

High-dose PPI therapy is clinically distinct from standard-dose therapy for specific diagnoses. Conditions such as severe erosive esophagitis, Barrett's esophagus, Zollinger-Ellison syndrome, and refractory GERD are recognized in clinical practice guidelines as indications for above-standard dosing regimens. If the prescribing clinician has documented a diagnosis that justifies the higher dose, the "duplicate" characterization is factually incorrect — the therapies serve different clinical goals. The appeal must establish the medical distinction between what the patient is already receiving and what is now being prescribed.

## Your Federal Appeal Rights

• Internal appeal: File under ERISA §503 (employer-sponsored plans) or applicable state law within the timeframe stated on the denial notice.
• External review: ACA §2719 entitles most plan members to independent external review after exhausting internal remedies. The standard window is approximately four months from the final internal denial. Request expedited review if the patient is experiencing active, severe symptoms.

## Concrete Appeal Steps and Timeline

1. Obtain the full denial letter identifying the specific drug(s) Cigna considers duplicative. 2. Confirm the patient's current active PPI prescriptions — drug name, dose, and prescriber — to understand exactly what Cigna flagged. 3. Have the prescribing clinician document why the current regimen is insufficient and why high-dose therapy is required for this patient's specific diagnosis. 4. Submit a Level 1 internal appeal with the clinical rationale and supporting records. 5. Escalate to external IRO review if the internal appeal is denied.

## Documentation to Gather

• Diagnosis documentation: Chart notes confirming the specific diagnosis that indicates high-dose therapy, including any relevant endoscopy, pathology, or pH-monitoring results.
• Treatment failure history: A chronological summary of prior standard-dose therapy — drug names, dates, doses, duration — and documented symptom persistence or objective findings showing inadequate response.
• Prescriber letter of medical necessity: A specific statement explaining that the high-dose prescription is not duplicating the existing regimen but escalating it in response to documented treatment failure or a diagnosis that inherently requires higher intensity acid suppression.
• Current medication reconciliation: A complete, current medication list demonstrating that the high-dose prescription is not a true duplicate but a clinically deliberate escalation.

## Criteria-Mapping Structure

Request Cigna's duplicate-therapy criteria from the denial letter or Cigna's published Clinical Policy Bulletins. For each stated basis for the duplicate finding, provide the clinical fact that distinguishes the high-dose prescription from the existing therapy. The core argument is that a qualitatively different diagnosis or a documented failure of the current regimen makes this a clinically necessary escalation, not a redundant prescription.